VEGFR3 does not sustain retinal angiogenesis without VEGFR2

Georgia Zarkada, Krista Heinolainen, Taija Makinen, Yoshiaki Kubota, Kari Alitalo

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Angiogenesis, the formation of new blood vessels, is regulated by vascular endothelial growth factors (VEGFs) and their receptors (VEGFRs). VEGFR2 is abundant in the tip cells of angiogenic sprouts, where VEGF/VEGFR2 functions upstream of the delta-like ligand 4 (DLL4)/Notch signal transduction pathway. VEGFR3 is expressed in all endothelia and is indispensable for angiogenesis during early embryonic development. In adults, VEGFR3 is expressed in angiogenic blood vessels and some fenestrated endothelia. VEGFR3 is abundant in endothelial tip cells, where it activates Notch signaling, facilitating the conversion of tip cells to stalk cells during the stabilization of vascular branches. Subsequently, Notch activation suppresses VEGFR3 expression in a negative feedback loop. Here we used conditional deletions and a Notch pathway inhibitor to investigate the cross-talk between VEGFR2, VEGFR3, and Notch in vivo. We show that postnatal angiogenesis requires VEGFR2 signaling also in the absence of Notch or VEGFR3, and that even small amounts of VEGFR2 are able to sustain angiogenesis to some extent. We found that VEGFR2 is required independently of VEGFR3 for endothelial DLL4 up-regulation and angiogenic sprouting, and for VEGFR3 functions in angiogenesis. In contrast, VEGFR2 deletion had no effect, whereas VEGFR3 was essential for postnatal lymphangiogenesis, and even for lymphatic vessel maintenance in adult skin. Knowledge of these interactions and the signaling functions of VEGFRs in blood vessels and lymphatic vessels is essential for the therapeutic manipulation of the vascular system, especially when considering multitargeted antiangiogenic treatments.

Original languageEnglish
Pages (from-to)761-766
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume112
Issue number3
DOIs
Publication statusPublished - 2015 Jan 20

Fingerprint

Blood Vessels
Vascular Endothelial Growth Factor Receptor
Lymphatic Vessels
Endothelium
Vascular Endothelial Growth Factors
Lymphangiogenesis
Embryonic Development
Signal Transduction
Up-Regulation
Endothelial Cells
Maintenance
Skin
delta protein
Therapeutics

Keywords

  • Anti-angiogenesis
  • Lymphangiogenesis
  • Notch
  • VEGFC
  • VEGFD

ASJC Scopus subject areas

  • General

Cite this

VEGFR3 does not sustain retinal angiogenesis without VEGFR2. / Zarkada, Georgia; Heinolainen, Krista; Makinen, Taija; Kubota, Yoshiaki; Alitalo, Kari.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 112, No. 3, 20.01.2015, p. 761-766.

Research output: Contribution to journalArticle

Zarkada, Georgia ; Heinolainen, Krista ; Makinen, Taija ; Kubota, Yoshiaki ; Alitalo, Kari. / VEGFR3 does not sustain retinal angiogenesis without VEGFR2. In: Proceedings of the National Academy of Sciences of the United States of America. 2015 ; Vol. 112, No. 3. pp. 761-766.
@article{31e86f884a4642b28e060e28f4413530,
title = "VEGFR3 does not sustain retinal angiogenesis without VEGFR2",
abstract = "Angiogenesis, the formation of new blood vessels, is regulated by vascular endothelial growth factors (VEGFs) and their receptors (VEGFRs). VEGFR2 is abundant in the tip cells of angiogenic sprouts, where VEGF/VEGFR2 functions upstream of the delta-like ligand 4 (DLL4)/Notch signal transduction pathway. VEGFR3 is expressed in all endothelia and is indispensable for angiogenesis during early embryonic development. In adults, VEGFR3 is expressed in angiogenic blood vessels and some fenestrated endothelia. VEGFR3 is abundant in endothelial tip cells, where it activates Notch signaling, facilitating the conversion of tip cells to stalk cells during the stabilization of vascular branches. Subsequently, Notch activation suppresses VEGFR3 expression in a negative feedback loop. Here we used conditional deletions and a Notch pathway inhibitor to investigate the cross-talk between VEGFR2, VEGFR3, and Notch in vivo. We show that postnatal angiogenesis requires VEGFR2 signaling also in the absence of Notch or VEGFR3, and that even small amounts of VEGFR2 are able to sustain angiogenesis to some extent. We found that VEGFR2 is required independently of VEGFR3 for endothelial DLL4 up-regulation and angiogenic sprouting, and for VEGFR3 functions in angiogenesis. In contrast, VEGFR2 deletion had no effect, whereas VEGFR3 was essential for postnatal lymphangiogenesis, and even for lymphatic vessel maintenance in adult skin. Knowledge of these interactions and the signaling functions of VEGFRs in blood vessels and lymphatic vessels is essential for the therapeutic manipulation of the vascular system, especially when considering multitargeted antiangiogenic treatments.",
keywords = "Anti-angiogenesis, Lymphangiogenesis, Notch, VEGFC, VEGFD",
author = "Georgia Zarkada and Krista Heinolainen and Taija Makinen and Yoshiaki Kubota and Kari Alitalo",
year = "2015",
month = "1",
day = "20",
doi = "10.1073/pnas.1423278112",
language = "English",
volume = "112",
pages = "761--766",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "3",

}

TY - JOUR

T1 - VEGFR3 does not sustain retinal angiogenesis without VEGFR2

AU - Zarkada, Georgia

AU - Heinolainen, Krista

AU - Makinen, Taija

AU - Kubota, Yoshiaki

AU - Alitalo, Kari

PY - 2015/1/20

Y1 - 2015/1/20

N2 - Angiogenesis, the formation of new blood vessels, is regulated by vascular endothelial growth factors (VEGFs) and their receptors (VEGFRs). VEGFR2 is abundant in the tip cells of angiogenic sprouts, where VEGF/VEGFR2 functions upstream of the delta-like ligand 4 (DLL4)/Notch signal transduction pathway. VEGFR3 is expressed in all endothelia and is indispensable for angiogenesis during early embryonic development. In adults, VEGFR3 is expressed in angiogenic blood vessels and some fenestrated endothelia. VEGFR3 is abundant in endothelial tip cells, where it activates Notch signaling, facilitating the conversion of tip cells to stalk cells during the stabilization of vascular branches. Subsequently, Notch activation suppresses VEGFR3 expression in a negative feedback loop. Here we used conditional deletions and a Notch pathway inhibitor to investigate the cross-talk between VEGFR2, VEGFR3, and Notch in vivo. We show that postnatal angiogenesis requires VEGFR2 signaling also in the absence of Notch or VEGFR3, and that even small amounts of VEGFR2 are able to sustain angiogenesis to some extent. We found that VEGFR2 is required independently of VEGFR3 for endothelial DLL4 up-regulation and angiogenic sprouting, and for VEGFR3 functions in angiogenesis. In contrast, VEGFR2 deletion had no effect, whereas VEGFR3 was essential for postnatal lymphangiogenesis, and even for lymphatic vessel maintenance in adult skin. Knowledge of these interactions and the signaling functions of VEGFRs in blood vessels and lymphatic vessels is essential for the therapeutic manipulation of the vascular system, especially when considering multitargeted antiangiogenic treatments.

AB - Angiogenesis, the formation of new blood vessels, is regulated by vascular endothelial growth factors (VEGFs) and their receptors (VEGFRs). VEGFR2 is abundant in the tip cells of angiogenic sprouts, where VEGF/VEGFR2 functions upstream of the delta-like ligand 4 (DLL4)/Notch signal transduction pathway. VEGFR3 is expressed in all endothelia and is indispensable for angiogenesis during early embryonic development. In adults, VEGFR3 is expressed in angiogenic blood vessels and some fenestrated endothelia. VEGFR3 is abundant in endothelial tip cells, where it activates Notch signaling, facilitating the conversion of tip cells to stalk cells during the stabilization of vascular branches. Subsequently, Notch activation suppresses VEGFR3 expression in a negative feedback loop. Here we used conditional deletions and a Notch pathway inhibitor to investigate the cross-talk between VEGFR2, VEGFR3, and Notch in vivo. We show that postnatal angiogenesis requires VEGFR2 signaling also in the absence of Notch or VEGFR3, and that even small amounts of VEGFR2 are able to sustain angiogenesis to some extent. We found that VEGFR2 is required independently of VEGFR3 for endothelial DLL4 up-regulation and angiogenic sprouting, and for VEGFR3 functions in angiogenesis. In contrast, VEGFR2 deletion had no effect, whereas VEGFR3 was essential for postnatal lymphangiogenesis, and even for lymphatic vessel maintenance in adult skin. Knowledge of these interactions and the signaling functions of VEGFRs in blood vessels and lymphatic vessels is essential for the therapeutic manipulation of the vascular system, especially when considering multitargeted antiangiogenic treatments.

KW - Anti-angiogenesis

KW - Lymphangiogenesis

KW - Notch

KW - VEGFC

KW - VEGFD

UR - http://www.scopus.com/inward/record.url?scp=84921417379&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921417379&partnerID=8YFLogxK

U2 - 10.1073/pnas.1423278112

DO - 10.1073/pnas.1423278112

M3 - Article

C2 - 25561555

AN - SCOPUS:84921417379

VL - 112

SP - 761

EP - 766

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 3

ER -